In a mouse model, a single dose of ATL-201 durably suppressed seizures and improved behavior through six months, according to the firm.

Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the publication of preclinical data in the journal ...

Nanotechnology offers a next-gen solution to plant genome editing challenges by enabling precise, efficient delivery of CRISPR, RNA, and DNA tools using nanoparticles like AuNPs, CNTs, and lipid ...

EMA orphan drug designation is awarded to drugs intended to treat rare diseases that are life-threatening or chronically debilitatingPreeclampsia, a serious obstetric complication, is a leading cause ...

Browse 270 market data Tables and 56 Figures spread through 254 Pages and in-depth TOC on "Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type ...

RNA therapeutics market is expanding, driven by advancements in gene therapy, personalized medicine, and RNA-based drug delivery, along with rising research in mRNA vaccines, antisense ...

Founded in 1980, Sarepta Therapeutics (NASDAQ:SRPT) is a biopharmaceutical company focused on developing precision genetic ...

The firm said its next-generation siRNA candidate showed in preclinical studies that it could reduce tumor growth and metastatic spread.

As antibody-drug conjugates (ADCs) advance in precision oncology, diagnostics play a vital role in identifying eligible patients, validating biomarkers and supporting regulatory approval. A ...

Discover how RNA therapeutics are reshaping medicine, offering new treatments for previously undruggable targets.

Novotech, a top global clinical trial provider, partners with biotech and pharma to speed siRNA therapeutic development.

First-ever positive profit, entering a new era of growth and global innovation SAN FRANSISCO and SUZHOU, China, March 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: ...